ATRC

SEC source: 0001336063-26-000002 · wk-form4_1772574779.xml · nonDerivative · entry 2

Privitera Salvatore · CIK 0001336063 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 171,175

F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

SEC source: 0001336063-26-000002 · wk-form4_1772574779.xml · nonDerivative · entry 1

Privitera Salvatore · CIK 0001336063 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 155,977

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001565823-26-000004 · wk-form4_1772574751.xml · nonDerivative · entry 3

Seith Douglas J · CIK 0001565823 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 229,340

F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

SEC source: 0001565823-26-000004 · wk-form4_1772574751.xml · nonDerivative · entry 2

Seith Douglas J · CIK 0001565823 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 252,288

F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

SEC source: 0001565823-26-000004 · wk-form4_1772574751.xml · nonDerivative · entry 1

Seith Douglas J · CIK 0001565823 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,756

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001565823-26-000002 · wk-form4_1767359181.xml · nonDerivative · entry 1

Seith Douglas J · CIK 0001565823 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,370

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended December 31, 2025.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 1, 2025, which is the first trading day of the applicable offering period. The closing price on July 1, 2025 was $32.20.

SEC source: 0001230584-25-000007 · wk-form4_1765545997.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 687,377

F1 · price: No consideration was received in connection with this charitable gift.

SEC source: 0001666600-25-000005 · wk-form4_1764193301.xml · nonDerivative · entry 1

Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,798

F1 · price: This transaction was executed in multiple trades at prices ranging from $36.51 to $38.44 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001205069-25-000007 · wk-form4_1764193388.xml · derivative · entry 6

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Non-qualified Stock Option (right to buy) · 4,967 shares

Expires 2026-11-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These options were granted on November 11, 2016. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.

SEC source: 0001205069-25-000007 · wk-form4_1764193388.xml · nonDerivative · entry 4

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,374

SEC source: 0001205069-25-000007 · wk-form4_1764193388.xml · nonDerivative · entry 3

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,341

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001205069-25-000007 · wk-form4_1764193388.xml · derivative · entry 5

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,967

Underlying: Non-qualified Stock Option (right to buy) · 5,033 shares

Expires 2026-11-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: These options were granted on November 11, 2016. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.

SEC source: 0001205069-25-000007 · wk-form4_1764193388.xml · nonDerivative · entry 2

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,374

F1 · price: This transaction was executed in multiple trades at prices ranging from $37.32 to $38.00 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001205069-25-000007 · wk-form4_1764193388.xml · nonDerivative · entry 1

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,407

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001323885-25-000105 · wk-form4_1764079265.xml · nonDerivative · entry 1

Yuen Maggie · CIK 0001796057 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,371

F1 · price: This transaction was executed in multiple trades at prices ranging from $35.71 to $35.76 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001230584-25-000005 · wk-form4_1763417459.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 691,377

F1 · price: No consideration was received in connection with this charitable gift.

SEC source: 0001666600-25-000003 · wk-form4_1758026753.xml · nonDerivative · entry 1

Noznesky Justin J · CIK 0001666600 · Chief Mktg & Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,964

F1 · price: This transaction was executed in multiple trades at prices ranging from $36.28 to $36.36 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001205069-25-000005 · wk-form4_1756211221.xml · derivative · entry 3

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Non-qualified Stock Option (right to buy) · 5,000 shares

Expires 2026-11-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These options were granted on November 11, 2016. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.

SEC source: 0001205069-25-000005 · wk-form4_1756211221.xml · nonDerivative · entry 2

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,374

SEC source: 0001205069-25-000005 · wk-form4_1756211221.xml · nonDerivative · entry 1

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,374

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001205069-25-000003 · wk-form4_1755781460.xml · derivative · entry 3

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Non-qualified Stock Option (right to buy) · 5,000 shares

Expires 2026-11-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These options were granted on November 11, 2016. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.

SEC source: 0001205069-25-000003 · wk-form4_1755781460.xml · nonDerivative · entry 2

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,374

SEC source: 0001205069-25-000003 · wk-form4_1755781460.xml · nonDerivative · entry 1

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,374

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001230584-25-000003 · wk-form4_1755001311.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 697,377

F1 · price: No consideration was received in connection with this charitable gift.

SEC source: 0001653877-25-000004 · wk-form4_1754658730.xml · nonDerivative · entry 1

GROVES REGINA E · CIK 0001653877 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,715

F1 · price: This transaction was executed in multiple trades at prices ranging from $36.75 to $36.84 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001862458-25-000003 · wk-form4_1754570700.xml · nonDerivative · entry 1

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,872

SEC source: 0001323885-25-000080 · wk-form4_1751460544.xml · nonDerivative · entry 1

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,372

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2025.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 2, 2025, which is the first trading day of the applicable offering period. The closing price on January 2, 2025 was $30.40.

SEC source: 0001323885-25-000077 · wk-form4_1751460512.xml · nonDerivative · entry 1

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,551

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2025.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 2, 2025, which is the first trading day of the applicable offering period. The closing price on January 2, 2025 was $30.40.

SEC source: 0001323885-25-000078 · wk-form4_1751460522.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 707,377

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2025.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 2, 2025, which is the first trading day of the applicable offering period. The closing price on January 2, 2025 was $30.40.

SEC source: 0001323885-25-000081 · wk-form4_1751460555.xml · nonDerivative · entry 1

Seith Douglas J · CIK 0001565823 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,113

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2025.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 2, 2025, which is the first trading day of the applicable offering period. The closing price on January 2, 2025 was $30.40.

SEC source: 0001323885-25-000079 · wk-form4_1751460533.xml · nonDerivative · entry 1

Privitera Salvatore · CIK 0001336063 · Chief Technical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,587

F1 · shares: Shares acquired pursuant to the AtriCure, Inc. 2018 Employee Stock Purchase Plan for the period ended June 30, 2025.

F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 2, 2025, which is the first trading day of the applicable offering period. The closing price on January 2, 2025 was $30.40.

SEC source: 0001323885-25-000071 · wk-form4_1748636330.xml · nonDerivative · entry 1

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,550

SEC source: 0001323885-25-000062 · wk-form4_1747860141.xml · nonDerivative · entry 1

Nachman Shlomo · CIK 0002006261 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,511

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-25-000059 · wk-form4_1747860104.xml · nonDerivative · entry 1

Telman Deborah H · CIK 0001860008 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,184

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-25-000061 · wk-form4_1747860128.xml · nonDerivative · entry 1

JOHNSON B KRISTINE · CIK 0001231984 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,810

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-25-000060 · wk-form4_1747860116.xml · nonDerivative · entry 1

WEHRWEIN SVEN · CIK 0001205069 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,374

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-25-000067 · wk-form4_1747861058.xml · nonDerivative · entry 1

Yuen Maggie · CIK 0001796057 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,371

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-25-000064 · wk-form4_1747860166.xml · nonDerivative · entry 1

WHITE ROBERT S. · CIK 0001571208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,174

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-25-000063 · wk-form4_1747860154.xml · nonDerivative · entry 1

Prange Karen · CIK 0001566083 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,229

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-25-000058 · wk-form4_1747860092.xml · nonDerivative · entry 1

GROVES REGINA E · CIK 0001653877 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,167

F1 · shares: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

SEC source: 0001323885-25-000048 · wk-form4_1746620705.xml · derivative · entry 2

WHITE ROBERT S. · CIK 0001571208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2025-05-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These options were granted on May 20, 2015. These options vest and are exercisable as to 25% of the shares one year from the date of grant and the remaining 75% thereafter vests and are exercisable in equal monthly installments on the same day of the month over the following three years.

SEC source: 0001323885-25-000048 · wk-form4_1746620705.xml · nonDerivative · entry 1

WHITE ROBERT S. · CIK 0001571208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,773

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001323885-25-000029 · wk-form4_1741810945.xml · nonDerivative · entry 1

CARREL MICHAEL H · CIK 0001230584 · Director · President, CEO, & Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 706,555

F1 · price: No consideration was received in connection with this gift to the reporting person's children.

SEC source: 0001323885-25-000027 · wk-form4_1741353680.xml · nonDerivative · entry 1

Prange Karen · CIK 0001566083 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,828

F1 · price: This transaction was executed in multiple trades at prices ranging from $37.60 to $38.52 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001323885-25-000023 · wk-form4_1741125647.xml · nonDerivative · entry 3

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,050

F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

SEC source: 0001323885-25-000023 · wk-form4_1741125647.xml · nonDerivative · entry 2

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,722

F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

SEC source: 0001323885-25-000023 · wk-form4_1741125647.xml · nonDerivative · entry 1

Doraiswamy Vinayak · CIK 0001862458 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,143

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.

SEC source: 0001323885-25-000019 · wk-form4_1741125591.xml · nonDerivative · entry 3

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,729

F3 · shares: The Reporting Person has elected to transfer these shares to the Company to satisfy the tax withholding obligation incurred upon the vesting and release of shares previously acquired pursuant to a Restricted Stock Award or Performance Share Award.

SEC source: 0001323885-25-000019 · wk-form4_1741125591.xml · nonDerivative · entry 2

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,599

F2 · price: The Reporting Person acquired these shares pursuant to the vesting and release of a Performance Share Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The award had Company performance goals and a service period requirement which were met.

SEC source: 0001323885-25-000019 · wk-form4_1741125591.xml · nonDerivative · entry 1

Dahlquist Karl S. · CIK 0001861996 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,020

F1 · price: The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. One third of the shares will vest annually upon the respective one, two, and three year anniversaries of the date of grant.